Bis-Trimethylbenzoyl Phenylphosphine Oxide is the organic compound.
产品中实际含有多少
暂无产品标示该成分含量。
含该成分的产品中，7 款将其列在 1% 线之前，0 款列在之后（通常不超过 1%）。
含有此成分的产品
已确认 7 款中的 7 款 · 按含量充足程度排序
定义
美国FDA 物质登记 · UNII JOV61FMS35 · 登记名称 BIS-TRIMETHYLBENZOYL PHENYLPHOSPHINE OXIDE · 单一化学物质
Bis-Trimethylbenzoyl Phenylphosphine Oxide is the organic compound.
化妆品中的作用
安全与法规参考
未列入韩国有毒物质 GHS 分类 · 现有化学物质
CIR reviewed this ingredient and flagged its status as: Insufficient Data Announcement: Safety Assessment of Bis Trimethylbenzoyl PhenylphosphineOxide, Ethyl Trimethylbenzoyl Phenylphosphinate, andTrimethylbenzoyl Diphenylphosphine Oxide (insufficient data or use not supported — CIR's own classification, not a full safety-as-used conclusion).
来源: 美国CIR 安全性评估
详细资料——标示名称、识别编号、物性、试验记录、文献
官方标示名称和定义
日本化妆品工业联合会标示名称 ビストリメチルベンゾイルフェニルホスフィンオキシド: 本品は、次の化学式で表される有機化合物である。
来源: 日本化妆品工业联合会标示名称
别名和识别信息
- CAS No.化学物质登记号
- 162881-26-7
- DTXSID美国EPA化学品编号
- DTXSID8044597
- DTXCID美国EPA化合物编号
- DTXCID6024597
- IUPAC
- Phenylbis(2,4,6-trimethylbenzoyl)-lambda~5~-phosphanone
- 分子式
- C26H27O3P
- 分子量
- 418.473 g/mol
产品实际使用的用途
这是向美国 EPA 申报含该成分的 13 款产品的用途。其中包括化妆品以外的产品，排在前几行的即为该成分的主要用途。
- Photosensitizers6
- Processing aids not otherwise specified3
- Photosensitive agent2
- Catalyst1
- Stabilizing agent1
来源: 美国EPA CompTox
刺激与致敏试验记录
记录有皮肤试验 15 项、眼部试验 5 项。
试验结论基本一致（100%）。 这是对原料本身的试验记录，与成品中所含浓度下的刺激性不同。
查看全部 20 项试验
- Skin Sens. 1
Skin Sensitization · Authoritative - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation), B.6 - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation) - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC, B.4 according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (Directive 92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (Maximisation) - Ambiguous
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) (1992) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) (Directive 92/69/EEC) - Ambiguous
skin sensitisation · Screening · according to other guideline: 92/69/EEC (Maximisation) - Category 6.5B (Category 1)
Skin Sensitization · Read Across - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: 92/69/EEC according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (92/69/EEC) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (Directive 92/69/EEC) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: 92/69/EEC, B.5 according to
来源: 美国EPA CompTox